News & Press Releases
News & Press Releases
News & Press Releases
Here you’ll find official announcements, company updates, and press releases from Psyence Biomed. This page provides verified, up-to-date information on our progress, partnerships, clinical milestones, and corporate developments.
We believe in keeping our stakeholders informed and engaged with clear and timely communication. Whether it’s news about our scientific breakthroughs, regulatory updates, or leadership commentary, this is your trusted source for all formal communications from Psyence Biomed.
All press releases are archived for reference and can be accessed at any time. For journalists or media professionals, please reach out to our team through the Contact page for further information or interviews.
Psyence BioMed Chief of Global Impact to speak at Psychedelic Science 2025
Psyence BioMed’s Chief of Global Impact, Mary-Elizabeth Gifford, joins PS2025’s Business Track as a featured speaker at the world’s top psychedelic science event.
Psyence BioMed Regains Full Compliance with Nasdaq Continued Listing Requirements
Psyence Biomedical Ltd. announced that it has received formal notification from the Nasdaq Hearings Panel confirming that the Company has regained compliance with all applicable Nasdaq continued listing requirements. This confirmation follows a successful compliance hearing held on May 29, 2025.
Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial
Psyence Biomed announced the finalization of its service agreement with Southern Star Research Pty Ltd (“Southern Star Research”), an award-winning, full-service Australian Contract Research Organization (CRO).
Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Psyence BioMed announced today that it received a notification letter dated April 16, 2025, from the Listings Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Rule”). The Staff's determination is based on the closing bid price of the Company’s common shares being below $1.00 for 30 consecutive business days from March 5, 2025 through April 15, 2025.
Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement
Psyence BioMed today announced a strategic follow-on investment of USD $500,000 into PsyLabs, a privately-held company specializing in the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for research, clinical trials, and drug development.
Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia
New partnership strengthens Psyence BioMed’s global clinical trial capabilities, accelerating the development of psilocybin-assisted therapy for adjustment disorder
News and Press Releases
Here you’ll find official announcements, company updates, and press releases from Psyence Biomed. This page provides verified, up-to-date information on our progress, partnerships, clinical milestones, and corporate developments.
We believe in keeping our stakeholders informed and engaged with clear and timely communication. Whether it’s news about our scientific breakthroughs, regulatory updates, or leadership commentary, this is your trusted source for all formal communications from Psyence Biomed.
All press releases are archived for reference and can be accessed at any time. For journalists or media professionals, please reach out to our team through the Contact page for further information or interviews.
